Abstract 12P
Background
Transcriptomic subtyping holds promise for personalized therapy in SCLC, but intratumoral transcriptomic heterogeneity and its clinical significance remain poorly defined. In this study, we aimed to assess transcription factor-defined subtypes within multiple regions of intact tissues and identify gene sets associated with long-term chemoimmunotherapy benefit.
Methods
We assessed baseline FFPE tumors from 26 ES-SCLC patients enrolled in the CANTABRICO clinical trial (EudraCT: 2020-002328-35). We used GeoMxTM DSP to perform transcriptomic analysis from multiple intratumoral regions of interest (ROIs). We used an assay with +1800 genes (GeoMxTM CTA) plus custom-designed and subsequently validated mRNA probes targeting subtype-defining transcription factors.
Results
We profiled 121 ROIs from 26 tumors. Cluster analysis based on ASCL1, NEUROD1, POU2F3 and YAP1 showed that all samples clustered within 3 groups: SCLC-A (58 ROIs, 47.93 %), SCLC-N (37 ROIs, 30.58 %) and SCLC-Y/I (26 ROIs, 21.49 %). SCLC-P subtype was not identified in this cohort. Gene set enrichment analysis (GSEA) using linear mixed models revealed that SCLC-A subtype was enriched in cell cycle and DNA damage repair genes and showed repression of multiple gene sets associated with anti-tumor immune response. SCLC-Y/I subtype showed the opposite pattern. Six patients (23%) had tumors with co-existence of more than one subtype, not evident through morphological inspection. Predominant subtype or the presence of subtype heterogeneity were not associated with outcomes. Tumors from patients with sustained benefit (time to progression >= 12 months) had mRNA profiles characterized by upregulation of interferon gamma (IFNg)-related genes and down-regulation of gen sets involved in glycolysis and aberrant metabolism.
Conclusions
This study reveals substantial intratumoral subtype heterogeneity in SCLC. In this limited cohort, we did not observe outcome significance for transcriptional subtypes. Our findings related to long-term treatment benefit require validation in independent cohorts.
Clinical trial identification
Data from patients enrolled in the CANTABRICO study (phase IIIb clinical trial, EudraCT 2020-002328-35).
Legal entity responsible for the study
Fundación OncoSur.
Funding
AstraZeneca.
Disclosure
C. Martí Cubells: Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca; Financial Interests, Personal, Other, Reimbursement of conference attendance: MSD, BMS, Merck. B. Massuti Sureda: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: MSD, Roche; Financial Interests, Institutional, Funding, Research on Tumor Board: BMS; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, MSD; Non-Financial Interests, Personal, Advisory Board: ASCO; Non-Financial Interests, Personal, Member: IASLC, SEOM; Non-Financial Interests, Personal, Leadership Role: SLCG. M. Majem: Financial Interests, Personal, Advisory Board: Amgen, Roche, AstraZeneca, Takeda, Janssen, Cassen Recordati, BMS; Financial Interests, Personal, Invited Speaker: Amgen, Roche, AstraZeneca, Pfizer, Takeda, Helsinn; Financial Interests, Institutional, Funding: BMS, AstraZeneca, Roche. M.R. García-Campelo: Financial Interests, Personal, Advisory Board: MSD, BMS, Roche, Boehringer Ingelheim, Medscape Pfizer, Novartis, AstraZeneca, Lilly, Takeda, Janssen, Sanofi; Financial Interests, Personal, Invited Speaker: MSD, BMS, Roche, Boehringer Ingelheim, Medscape Pfizer, Novartis, AstraZeneca, Lilly, Takeda, Janssen, Sanofi; Financial Interests, Personal, Principal Investigator: MSD, BMS, Roche, Boehringer Ingelheim, Medscape Pfizer, Novartis, AstraZeneca, Lilly, Takeda, Janssen, Sanofi. P. Diz Tain: Financial Interests, Personal, Invited Speaker: BMS, AstraZeneca, Boehringer Ingelheim, Roche, MSD, Takeda, Pfizer, Amgen; Financial Interests, Personal, Advisory Role: BMS, AstraZeneca, Boehringer Ingelheim, Roche, MSD; Financial Interests, Personal, Training: BMS, AstraZeneca, Boehringer Ingelheim, Roche, MSD, Takeda, Pfizer; Financial Interests, Institutional, Principal Investigator: AstraZeneca, Roche, Mirati; Financial Interests, Personal, Advisory Board: Takeda. M.D. Isla Casado: Financial Interests, Personal, Speaker, Consultant, Advisor, Consultation and speaker honoraria: Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, F. Hoffmann-La Roche, Janssen, MSD, Pfizer, Takeda; Financial Interests, Personal, Speaker, Consultant, Advisor, Consultation honoraria: Lilly, Merck, Sanofi; Financial Interests, Personal, Speaker, Consultant, Advisor, Speaker honoraria: Novartis; Financial Interests, Institutional, Other, Clinical trial: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, F. Hoffmann-La Roche, GSK, Janssen, Lilly, Merck, Mirati Therapeutics, MSD, Novartis, Pfizer, Sanofi; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS, F. Hoffmann-La Roche, GSK; Other, Personal, Member of Board of Directors, Executive board member: Commission for the Approval of New Drugs, Regional Health Care Department (Spain). A. Moreno Paul: Financial Interests, Personal, Invited Speaker: Roche, MSD, Bristol; Financial Interests, Personal, Other, Reimbursement of conference attendance: Roche, MSD. E. Conde Gallego: Financial Interests, Personal, Research Funding: Roche, ThermoFisher; Financial Interests, Personal, Other, Honoraria: Roche, Lilly, Pfizer, AstraZeneca, Janssen. L. Paz-Ares: Financial Interests, Personal, Advisory Board, Speaker fees: Roche, MSD, BMS, AZ, Lilly, PharmaMar, BeiGene, Daichii, Medscape, PER; Financial Interests, Personal, Advisory Board: Merck Serono, Pfizer, Bayer, Amgen, Janssen, GSK, Novartis, Takeda, Sanofi, Mirati; Financial Interests, Personal, Other, Board member: Genomica, Altum sequencing; Financial Interests, Personal, Member of Board of Directors, Board member: Stab Therapeutics; Financial Interests, Institutional, Coordinating PI: Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme corp, BMS, Janssen-Cilag international NV, Novartis, Roche, Sanofi, Tesaro, Alkermes, Lilly, Takeda, Pfizer, PharmaMar; Financial Interests, Personal, Coordinating PI: Amgen; Financial Interests, Personal, Other, Member: AACR, ASCO, ESMO; Financial Interests, Personal, Other, Foundation Board Member: AECC; Financial Interests, Personal, Other, President: ASEICA (Spanish Association of Cancer Research); Financial Interests, Personal, Other, Foundation president: ONCOSUR; Financial Interests, Personal, Other, member: Small Lung Cancer Group. J. Zugazagoitia: Financial Interests, Personal, Speaker, Consultant, Advisor, Consultant: Sanofi, AstraZeneca, BMS, Roche, Pfizer, Novartis, Guardant Health; Financial Interests, Personal, Invited Speaker: Sanofi, Takeda, BMS, Pfizer, Roche, AstraZeneca, NanoString, Guardant Health; Financial Interests, Personal, Other, Travel honoraria: Sanofi, Takeda, BMS, Pfizer, Roche, AstraZeneca, NanoString; Financial Interests, Institutional, Research Funding: BMS, AstraZeneca, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
181P - Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Presenter: Jitka Palich Fucikova
Session: Poster Display
182P - Exploring Cross-Compartmental Tumor Cell Plasticity and Immunogenicity in Serous Ovarian Cancer
Presenter: Louisa Hell
Session: Poster Display
183P - Multi-omics Investigation Reveals Cancer-Associated Fibroblast-Secreted FGF7 as an Ovarian Cancer Progression Promoter through HIF-1_/EMT Modulation
Presenter: Songwei Feng
Session: Poster Display
184P - Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study.
Presenter: LUCIA CARRIL AJURIA
Session: Poster Display
185P - The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma
Presenter: Yazan Al Zu’bi
Session: Poster Display
186P - Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: an EORTC IMMUcan sub-project
Presenter: Athénaïs Van Der Elst
Session: Poster Display
187P - Local and systemic anti-tumor response during tumor development in an immune privileged site: the case of uveal melanoma
Presenter: Francesca Lucibello
Session: Poster Display
188P - Expression of the co-stimulatory checkpoint protein OX40L (TNFSF4) in the melanoma micro-environment
Presenter: Raya Leibowitz-Amit
Session: Poster Display
189P - The impact of immune microenvironment subopopulations on soft tissue sarcomas
Presenter: Shokhrukhbek Khujaev
Session: Poster Display